Download or read book Antibody Drug Conjugates and Immunotoxins written by Gail Lewis Phillips and published by Springer Science & Business Media. This book was released on 2012-12-13 with total page 370 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
Download or read book Next Generation Antibody Drug Conjugates ADCs and Immunotoxins written by Ulf Grawunder and published by Springer. This book was released on 2017-04-07 with total page 191 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.
Download or read book Antibody Drug Conjugates and Immunotoxins written by Gail Lewis Phillips and published by Springer. This book was released on 2012-12-12 with total page 378 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
Download or read book Cytotoxic Payloads for Antibody Drug Conjugates written by David E Thurston and published by Royal Society of Chemistry. This book was released on 2019-07-15 with total page 502 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (Kadcyla™), brentuximab vedotin (Adcetris™), inotuzumab ozogamicin (Besponsa™), gemtuzumab ozogamicin (Mylotarg™) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity. Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future.
Download or read book Antibody Drug Conjugates written by Jeffrey Wang and published by Springer. This book was released on 2015-03-05 with total page 248 pages. Available in PDF, EPUB and Kindle. Book excerpt: This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.
Download or read book Antibody Drug Conjugates written by Laurent Ducry and published by Humana Press. This book was released on 2013-08-03 with total page 317 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular BiologyTM format, these detailed chapters include the kind of practical implementation advice that guarantees quality results. Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.
Download or read book Conjugates and Malignant Disease written by Michael Magerstadt and published by CRC Press. This book was released on 1991-01-03 with total page 246 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive overview of antibody conjugates for in vivo applications. It discusses each of the major classes of antibody conjugates used in cancer diagnosis and therapy, as well as the major chemical and biological aspects of antibody selection, conjugate preparation, characterization, and application. The book is designed to close the information gap that exists regarding these compounds between such diverse disciplines as radiochemists, immunochemists, oncologists, clinicians and immunologists. It also provides a thorough overview for newcomers to the field.
Download or read book Antibody Drug Conjugates written by Kenneth J. Olivier, Jr. and published by John Wiley & Sons. This book was released on 2016-11-14 with total page 474 pages. Available in PDF, EPUB and Kindle. Book excerpt: Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. • Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies • Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging • Includes case studies of ADCs in oncology drug development • Features contributions from highly-regarded experts on the frontlines of ADC research and development
Download or read book Antibody Drug Conjugates and Cellular Metabolic Dynamics written by Shuqing Chen and published by Springer Nature. This book was released on 2023-04-18 with total page 139 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book summarizes the related research achievements in Antibody-drug conjugates (ADCs) and their cell metabolism kinetics. The book has three main parts. The first part describes the basic theory of ADCs, including the basic concept and structure of ADCs, and the relationship between the targets of ADCs and their specific functions. The second part mainly introduces the endocytosis and intracellular metabolism of ADCs, including the relationship between endocytosis and ADC activity, the endocytosis and intracellular transport of ADCs, the distribution and metabolism of ADC in vivo. Then it discusses the new formats and research technology of ADCs, including the application of miniaturized antibodies in ADC synthesis, novel carriers for ADC design, the technology and application of site-specific conjugation, and approaches for analyzing the drug: antibody ratio (DAR), the study of pharmacokinetics of ADCs. This book combines the basic theory with the research technology. It can be used as a reference book for students, teachers and researchers of biomedical field.
Download or read book Innovations for Next Generation Antibody Drug Conjugates written by Marc Damelin and published by Springer. This book was released on 2018-05-29 with total page 357 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Download or read book Immunoconjugates written by Carl-Wilhelm Vogel and published by Oxford University Press, USA. This book was released on 1987 with total page 330 pages. Available in PDF, EPUB and Kindle. Book excerpt: Immunoconjugate research aims to develop improved methods of cancer detection and more effective, efficient drugs to combat cancer. This book contains contributions from virtually all established research groups in the immunotoxin field and offers a comprehensive discussion of current and potential applications of immunoconjugates, covering all pertinent topics from chemical synthesis to clinical trial.
Download or read book Antibody Carriers of Drugs and Toxins in Tumor Therapy written by and published by . This book was released on 1982 with total page 228 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Biotin and Other Interferences in Immunoassays written by Amitava Dasgupta and published by Elsevier. This book was released on 2019-01-15 with total page 144 pages. Available in PDF, EPUB and Kindle. Book excerpt: Biotin and Other Interferences in Immunoassays: A Concise Guide is aimed at clinical laboratory scientists, medical technologists and pathologists who are often the first individuals contacted by a clinician when a laboratory test result does not correlate with clinical presentation. Research scientists working in diagnostics companies will also find this information essential. Sources of errors in non-immunoassay based methods used in clinical chemistry and toxicology laboratory are also discussed so readers can get all important information from one concise guide. This succinct, user-friendly reference provides the necessary information to address high levels of biotin in clinical laboratory results. Discusses issues of biotin interferences and ways to avoid them for accurate clinical laboratory results Provides sources of errors in non-immunoassay based methods used in clinical chemistry and toxicology laboratories Highlights how to handle specimens in the lab and how to eliminate the effect of biotin in precious samples
Download or read book Antibody Drug Conjugates written by Laurent Ducry and published by Humana. This book was released on 2016-08-23 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular BiologyTM format, these detailed chapters include the kind of practical implementation advice that guarantees quality results. Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.
Download or read book Immunotoxins written by Arthur E. Frankel and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 550 pages. Available in PDF, EPUB and Kindle. Book excerpt: Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good indepth reviews of cancer topics, and published symposium lectures are often the best overviews available. Un fortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up-to-date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by dividing the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more.
Download or read book Antibody Toxin Conjugates written by Deirdre P. McIntosh and published by . This book was released on 1984 with total page 29 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Macromolecular Anticancer Therapeutics written by L. Harivardhan Reddy and published by Springer Science & Business Media. This book was released on 2010-03-20 with total page 627 pages. Available in PDF, EPUB and Kindle. Book excerpt: In spite of the development of various anticancer drugs, the therapy of cancer has remained challenging for decades. The current therapy of cancer is overwhelmed because of the inability to deliver therapeutics to all regions of a tumor in effective therapeutic concentrations, intrinsic or acquired resistance to the treatment with currently available agents via genetic and epigenetic mechanisms, and toxicity. As a result, cancer therapy using conventional therapeutics and different types of treatment regimens using this therapeutics has not led to a convincing survival benefit of the patients. In this context, Macromolecular therapeutics offer several advantages over conventional low molecular therapeutics by various ways such as, enable the use of larger doses of these agents by limiting the toxicity, by enhanced permeability and retention into tumors, by tumor targeting using tumor-specific antibodies, by specific inhibition of oncogenes using anticancer oligonucleotides etc. Cancer treatment using this macromolecular therapeutics has considerably improved the survival benefit for patients. As a result, various macromolecular therapeutics are already commercialized or are under clinical development. Although we are far from a real magic bullet today, looking at the pace of research and current success in this field of macromolecular therapeutics, it appears that we are approaching a magic bullet for the efficient treatment of cancer. Thus, we believe that the subject of this book is very timely, and that the book will fill an unmet need in the market. This book is unique and assembles various types and aspects of macromolecular anticancer therapeutics for cancer therapy in one shell and conveys the importance of this interdisciplinary field to the broad audience. Thus, in a nutshell, this book details the basics of cancer, and various therapeutic strategies such as those based on macromolecular therapeutics hence can become an important reference for practitioners, oncologists, medical pharmacologists, medicinal chemists, biomedical scientists, experimental pharmacologists, pharmaceutical technologists, and particularly it can essentially become a handbook of macromolecular therapeutics for cancer therapy for graduates, post-graduates and Ph.D. students in these fields.
